Dr. Saenger on Combining Targeted and Immune Agents

Video

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the idea of combining targeted and immune agents.

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the idea of combining targeted and immune agents.

It is very attractive to combine these two types of agents, Saenger says, as targeted agents knock down the tumor burden; however, they generally do not produce long term responses. Additionally, when a large tumor is present, a patient is less likely to respond to immunotherapy, as the tumor is generally immunosuppressive.

The concept behind the phase II CA184-240 study in advanced melanoma is to hit the tumor with vemurafenib, a BRAF inhibitor, then administer ipilimumab, an CTLA-4-targeted immunotherapy. However, unfortunately, a previous trial using these drugs simultaneously demonstrated liver toxicity.

<<<

View more from the 2013 ASCO Annual Meeting

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,